Evropska unija - slovaščina - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunavir - hiv infekcie - antivirotiká na systémové použitie - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):na liečbu hiv-1 infekcie v antiretrovirálnej liečby (umenia)-skúsený dospelých pacientov, vrátane tých, ktoré boli vysoko upravená. na liečbu hiv-1 infekcie u pediatrických pacientov vo veku od 3 rokov a najmenej na 15 kg telesnej hmotnosti. pri rozhodovaní, či začať liečbu s darunavir spoločne spravované s nízkymi dávkami ritonavirom, starostlivo by sa mali zvážiť liečbu histórii jednotlivých pacientov a vzory mutácie spojené s rôznymi látkami. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 a 5. darunavir spoločne spravované s nízkymi dávkami ritonavirom je indikovaný v kombinácii s inými antiretrovirálnej lieky na liečbu pacientov so vírus ľudského imunodeficiencie (hiv-1) infekcie.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. pri rozhodovaní, či začať liečbu s darunavir v takýchto umenie-skúsený pacientov, genotypic testovanie by sa malo riadiť použitie darunavir (pozri časť 4. 2, 4. 3, 4. 4 a 5.

Slovaška - slovaščina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovaška - slovaščina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovaška - slovaščina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovaška - slovaščina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovaška - slovaščina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Evropska unija - slovaščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Slovaška - slovaščina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovaška - slovaščina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Evropska unija - slovaščina - EMA (European Medicines Agency)

gilead sciences ireland unlimited company - lenacapavir sodium - hiv infekcie - antivirotiká na systémové použitie - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 a 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 a 5.